|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University of Bergen |
| Information provided by: | University of Bergen |
| ClinicalTrials.gov Identifier: | NCT00295386 |
Purpose
The present study examines the short- and long-term clinical efficacy of cognitive-behavior therapy and pharmacological treatment in patients suffering from late-life primary insomnia. 46 subjects suffering from chronic primary insomnia were randomized into either cognitive-behavior therapy (CBT, n=18), hypnotics (7.5 mg Zopiclone, n=16), or placebo treatment (n=12). All active treatments lasted 6 weeks with follow-ups conducted at 6 months. Ambulant clinical polysomnography (PSG) and sleep diaries were used on all three assessment points.
| Condition | Intervention | Phase |
|
Insomnia |
Behavioral: Cognitive behavior therapy (CBT) Drug: Zopiclone |
Phase IV |
| Drug Information available for: | Zopiclone |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Eligibility
| Ages Eligible for Study: | 55 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | REK Vest nr. 186.03 |
| First Received: | February 21, 2006 |
| Last Updated: | July 17, 2006 |
| ClinicalTrials.gov Identifier: | NCT00295386 |
| Health Authority: | Norway: Norwegian Medicines Agency |
|
|
|